Research and Markets: Anti-Infective Drugs Markets: Six Infectious Diseases Account for 50% of Premature Deaths Worldwide

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of the "Anti-Infective Drugs Markets" report to their offering.

Six infectious diseases - pneumonia, tuberculosis, diarrheal diseases, malaria, measles and HIV/AIDS - account for half of all premature deaths worldwide, killing mostly children and young adults, according to the World Health Organization (WHO). Moreover, threatening pandemics such as swine flu (H1N1 influenza A virus) are adding significant pressure to already strained healthcare budgets of governments around the world.

This report analyzes the anti-infective drugs market and highlights the existing and developing anti-infectives used to ameliorate infectious diseases' afflictions on humankind. Anti-infective drugs include: anti-viral therapeutics, antibiotics, anti-fungal agents and prophylactic treatments such as vaccines. Particular attention is paid to the clinical market segment and the pharmaceutical/biotechnology companies involved in anti-infective drugs with specific emphasis on each company's sales focus, product portfolio and R&D pipeline.

To date, the most successful anti-infective drugs target the human immunodeficiency virus (HIV, the virus that causes AIDS), the herpes virus (HSV-1 and HSV-2), bacterial infections and hepatitis C (HCV). A number of exciting novel anti-viral and antibiotic compounds are currently revolutionizing anti-infective drugs markets, including Truvada and Valtrex, which are anti-HIV and anti-herpes therapies, respectively. Significant resources are also being dedicated toward hepatitis A (HAV), hepatitis B (HBV) and Staph infections, including MRSA.

What's more, this study will examine the existing and developing anti-infective drugs targeted at infectious diseases that continue to devastate developing countries, including: cholera, dengue fever, meningitis, rotavirus, typhoid and yellow fever.

Key Topics Covered:

  • Overview
  • Clinical Syndromes and Therapy
  • Anti-Infective Drugs Market
  • Description of Anti-Infective Therapeutic Agents
  • Market for Anti-Infective Drugs and Vaccines
  • Decision-making Activity in the Anti-Infective Drugs Market
  • Economics of Anti-Microbial Drug Resistance: The Persistent Need for Anti-Bacterials
  • Global Market Analysis of Anti-Infective Drugs
  • Global Market for Anti-Bacterial Therapies
  • Global Market for Anti-Fungal Therapies
  • Global Market for Anti-Viral Therapies
  • Market, Demographic and Economic Trends
  • Political/Legal Trends
  • Technological Trends
  • Socio-Cultural Trends
  • Competitive Landscape
  • Sales Performance amongst the Leading Players: Detailed Analysis of Leading Anti-Infective Players
  • Company Profiles

Companies Mentioned:

  • Adlyfe, Inc.
  • Advanced Life Sciences Holdings, Inc.
  • Affinium Pharmaceuticals
  • APP Pharmaceuticals
  • Aquapharm Biodiscovery
  • Basilea Pharmaceutica AG
  • Biophage Pharma, Inc.
  • CEL-SCI Corporation
  • Cerexa, Inc. (Subsidiary of Forest Laboratories)
  • Daiichi Sankyo Co., Ltd.
  • Hospira, Inc.
  • Incyte Corporation
  • Idenix Pharmaceuticals, Inc.
  • Medivir AB
  • Mutabilis
  • NanoBio Corporation
  • Nanosphere, Inc.
  • Novabay Pharmaceuticals, Inc.
  • Obetech, LLC
  • Optimer Pharmaceuticals, Inc.
  • Panacos Pharmaceuticals, Inc.
  • Paratek Pharmaceuticals, Inc.
  • Pharmasset, Inc.
  • Ribomed Biotechnologies, Inc.
  • Rib-X Pharmaceuticals, Inc.
  • Targanta Therapeutics Corporation, Inc. (Acquired by The Medicine Company)
  • Trius Therapeutics
  • Vertex Pharmaceuticals, Inc.
  • X-GEN Pharmaceuticals, Inc.

For more information visit


Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
[email protected]


INDUSTRY KEYWORDS:   Health  Infectious Diseases  Pharmaceutical



Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.